These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 18283785)
1. The 5q- syndrome. Giagounidis AA; Aul C Cancer Treat Res; 2008; 142():133-48. PubMed ID: 18283785 [No Abstract] [Full Text] [Related]
2. Myelodysplastic syndrome with isolated 5q deletion (5q- syndrome). A clonal stem cell disorder characterized by defective ribosome biogenesis. Cazzola M Haematologica; 2008 Jul; 93(7):967-72. PubMed ID: 18591621 [No Abstract] [Full Text] [Related]
3. The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes. Melchert M; Kale V; List A Curr Opin Hematol; 2007 Mar; 14(2):123-9. PubMed ID: 17255789 [TBL] [Abstract][Full Text] [Related]
13. A delayed yet durable response to very short lenalidomide therapy and unexpected clone redistribution in a case of myelodysplastic syndrome with del(5q) and del(20q). Xu F; Li X; Chang C; He Q; Zhang Z; Zhang Q; Wu L Leuk Res; 2009 Nov; 33(11):e199-202. PubMed ID: 19592091 [No Abstract] [Full Text] [Related]
14. 5q-syndrome presenting as essential thrombocythemia: myelodysplastic syndrome or chronic myeloproliferative disorders? Koike T; Uesugi Y; Toba K; Narita M; Fuse I; Takahashi M; Shibata A Leukemia; 1995 Mar; 9(3):517-8. PubMed ID: 7885050 [No Abstract] [Full Text] [Related]
15. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era. Holtan SG; Santana-Davila R; Dewald GW; Khetterling RP; Knudson RA; Hoyer JD; Chen D; Hanson CA; Porrata L; Tefferi A; Steensma DP Am J Hematol; 2008 Sep; 83(9):708-13. PubMed ID: 18634051 [TBL] [Abstract][Full Text] [Related]
16. Low frequency of the glutathione-S-transferase T1-null genotype in patients with primary myelodysplastic syndrome and 5q deletion. Stavropoulou C; Sambani C; Rigana H; Georgakakos VN; Voutsinas G; Manola KN; Pantelias GE; Makropoulos V; Leukemia; 2008 Aug; 22(8):1643-6. PubMed ID: 18305556 [No Abstract] [Full Text] [Related]
17. Unusual clonal evolution involving 5q in a case of myelodysplastic syndrome with deletion 5q 31 treated with lenalidomide. Eclache V; Da Rocha A; Le Roux G; Fenaux P Haematologica; 2008 Feb; 93(2):315-6. PubMed ID: 18245660 [TBL] [Abstract][Full Text] [Related]
18. The role of lenalidomide in the management of myelodysplasia with del 5q. Kelaidi C; Eclache V; Fenaux P Br J Haematol; 2008 Feb; 140(3):267-78. PubMed ID: 18217896 [TBL] [Abstract][Full Text] [Related]
19. Dihydrofolate reductase activity in the erythroblasts of patients with 5q- syndrome. Nano R; Invernizzi R; Pecci A; Civallero M; Gerzeli G Haematologica; 2000 Jul; 85(7):765-6. PubMed ID: 10897132 [No Abstract] [Full Text] [Related]
20. [Apropos of the case "Erythroblastopenia associated with myelodysplastic syndrome"]. Aventín A Sangre (Barc); 1996 Dec; 41(6):483. PubMed ID: 9148428 [No Abstract] [Full Text] [Related] [Next] [New Search]